Humanoid Global provides update on RideScan’s commercialization progress

Humanoid Global Holdings Corp. (Humanoid Global), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in the humanoid robotics and embodied AI sector, has provided an update from RideScan.

RideScan is a Scotland-based AI platform focused on proactively addressing reliability, safety and efficiency to optimize the performance of autonomous robots. Humanoid Global said RideScan serves as the “safety layer” on these robots and is suitable for deployment across industries, compatible with a range of diverse hardware and software platforms.

Humanoid Global announced its investment in RideScan in September 2025.

RideScan files patent application in United Kingdom

RideScan has recently filed its foundational patent application with the United Kingdom Intellectual Property Office, which seeks to protect its unique approach to independent risk scoring and anomaly detection in robotics. Humanoid Global said this patent-pending technology is intended to further strengthen RideScan’s position as a trusted leader in robotic safety and reliability, enabling applications ranging from mission-level risk assessment to proactive maintenance and certification support.

RideScan is also entering pilot deployments across humanoid, robot and industrial robotics ecosystems. Humanoid Global said these pilots are expected to demonstrate RideScan’s ability to provide independent, AI-driven insights into robot health and performance, ensuring safer more reliable deployments at scale.

“At RideScan, we continue to progress our mission to ensure every robot can be trusted to operate safely and reliably,” said Dr. Shivoh Chirayil Nandakumar, CEO of RideScan. “Filing our foundation patent marks a major step in protecting the technology behind that vision, and our upcoming pilots are expected to show how this innovation can help transform the way robots are deployed around the world.” 

RideScan is assembling a cohort of 10 organizations to begin integrating its API across a range of robotics platforms. Shortlisted candidates include engineers and teams from research institutions and corporations in the robotics field. The purpose of the cohort is to demonstrate RideScan’s ability to reduce downtime by identifying issues before they escalate, enhance operational safety and reliability through independent robotic health checks, and uncover hidden anomalies that are often missed by traditional monitoring systems.

RideScan was recently awarded £50,000 from the Innovate UK Growth Catalyst Early Stage: New Innovators grant, supporting the continued expansion and commercialization of its core technology, with execution beginning on November 1, 2025. RideScan has also received another investment of £40,000 from a Europe-based deep-tech-focused angel syndicate, including research scientists from a subsidiary of a Fortune 500 company specializing in artificial intelligence research.

“We are pleased with RideScan's advancements, from filing their foundational patent to launching pilot cohorts and securing key grants and investments,” said Shahab Samimi, CEO of Humanoid Global. “We believe that this progress not only fortifies our portfolio's focus on safe, scalable robotics but also positions RideScan as a cornerstone in enabling trustworthy AI-driven deployments worldwide.”